Journal
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 22, Issue 5, Pages 831-847Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2008.07.001
Keywords
bisphosphonates; bone turnover; bone strength; fractures; pharmacokinetics; pharmacodynamics
Categories
Ask authors/readers for more resources
Bisphosphonates (BPs) are taken up preferentially by the skeleton and decrease osteoclast-mediated bone resorption. The capacity of the skeleton to retain BPs is large, and there is no indication for saturation of binding sites with the doses used in osteoporosis. The antiresorptive action of BPs includes their selective binding to calcium crystals and their subsequent release and uptake by the osteoclasts. There are differences in the affinities of PBs for bone as well as in their anti-resorptive potencies, and the whole molecule is responsible for their inhibitory effect on bone resorption. At the tissue level, they decrease the rate of bone resorption and turnover, increase bone mineral density, and maintain or improve structural and material properties of bone and thereby reduce the risk of fractures. Current studies address questions related primarily to the pharmacological properties of these compounds that are essential for their optimal clinical use, such as for example long-term safety and efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available